Fangusaro, J. R., Onar-Thomas, A., Poussaint, T. Y., Wu, S., Ligon, A. H., Lindeman, N. I., … Dunkel, I. J. (2022). Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study. Neuro Oncol, 24(8), 1404. https://doi.org/10.1093/neuonc/noac029

Fangusaro, Jason R., Arzu Onar-Thomas, Tina Young Poussaint, Shengjie Wu, Azra H. Ligon, Neal Ian Lindeman, Anuradha Banerjee, et al. “Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.” Neuro Oncol 24, no. 8 (August 1, 2022): 1404. https://doi.org/10.1093/neuonc/noac029.

Fangusaro JR, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman NI, et al. Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study. Neuro Oncol. 2022 Aug 1;24(8):1404.

Fangusaro, Jason R., et al. “Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.” Neuro Oncol, vol. 24, no. 8, Aug. 2022, p. 1404. Pubmed, doi:10.1093/neuonc/noac029.

Fangusaro JR, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman NI, Banerjee A, Packer R, Kilburn LB, Pollack IF, Qaddoumi IA, Fisher PG, Dhall G, Baxter PA, Kreissman SG, Doyle LA, Smith MA, Fouladi M, Dunkel IJ. Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study. Neuro Oncol. 2022 Aug 1;24(8):1404.